Previous Article | Next Article 
Journal of Clinical Microbiology, October 2004, p. 4885-4888, Vol. 42, No. 10
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.10.4885-4888.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Pediatric Infection Due to Multiresistant Salmonella enterica Serotype Infantis in Honduras
Ernesto Liebana,1* Miranda Batchelor,2 Carmen Torres,3 Laura Briñas,3 Luis A. Lagos,4 Baha Abdalhamid,5 Nancy D. Hanson,5 and Jaime Martinez-Urtaza2
Instituto de Acuicultura, Universidad de Santiago de Compostela, Santiago de Compostela,1
Area de Bioquimica y Biologia Molecular, Universidad de La Rioja, Logro
o Spain,3
Veterinary Laboratories Agency, DEFRA, Addlestone, United Kingdom,2
Laboratorio Central de Microbiología, Secretaría de Salud, Tegucigalpa, Honduras,4
Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska5
Received 16 February 2004/
Returned for modification 29 April 2004/
Accepted 19 June 2004

ABSTRACT
We report the case of a pediatric patient with a
Salmonella enterica serotype Infantis infection. Detailed microbiological
investigation revealed that this isolate carries four ß-lactamase
genes (
blaTEM-1b variant,
blaSHV-5,
blaCTX-M-15, and
blaCMY-2)
conferring resistance to all ß-lactams but imipenem.
This is the first report of a
Salmonella isolate with CTX-M
and AmpC enzymes on the American continent, the first report
of
blaCMY-2 in
Salmonella serotype Infantis, and the first report
of
blaCTX-M-15 in the genus
Salmonella.

CASE REPORT
In August 2002, an 18-month-old infant male with a clinical
syndrome indicating an enteritis-like infection was admitted
to the Santa Teresa Hospital in Comaguaya (Honduras). The patient,
whose symptoms began 3 days before admission, presented with
a fever up to 40°C, mucous bloody diarrhea, nausea, and
vomiting. His urine was cloudy, with a pH of 5, and laboratory
analysis showed elevated numbers of red blood cells (4/field),
white blood cells (6/field), and granular casts (6/field). Laboratory
analysis of fecal samples revealed the presence of erythrocytes
(4/field) and neutrophils (15/field). Because of limited resources
available at the hospital, no microbiological techniques were
performed on these samples. An empirical treatment without a
confirmatory microbiological diagnosis was immediately initiated
with intravenous amikacin (50 mg every 12 h) and intravenous
ceftriaxone (350 mg every 12 h) and continued for 9 days. Oral
anti-inflammatory drugs (acetaminophen) to control pain and
fever were also administered, and the patient was rehydrated
intravenously as required. The condition of the patient improved
(fever decreased to normal temperature values, and vomiting
and diarrhea ceased), and he was discharged from the hospital.
Two weeks later, the patient returned with a relapse of the
symptoms and severe malnutrition. A second empirical treatment
consisting of intravenous amikacin (40 mg every 12 h) and cefoxitin
(250 mg every 6 h) was administered for 9 days. At the time
of the second admission, urine and stool samples were collected
and sent to the Laboratorio Central de Microbiologia in Tegucigalpa,
Honduras, for microbiological analysis. Both samples were confirmed,
by following standard methods, as positive for the isolation
of
Salmonella sp. (preenrichment of the sample in tetrathionate
broth, followed by plating on Taylor's xylose lysine deoxycholate
agar). The laboratory values for the hemogram were 3.18 million
red blood cells/mm
3, 8,800 white blood cells/mm
3, 2,200 lymphocytes/mm
3,
165,000 platelets/mm
3, a hematocrit of 21.9%, a hemoglobin concentration
of 7.6 g/dl, a mean corpuscular hemoglobin level of 23.9 pg,
a mean corpuscular hemoglobin concentration of 34.7 g/dl, and
a mean corpuscular volume of 69 fl. All of these values were
consistent with a loss of blood and reflected the presence of
anemia in the patient. Screening for human immunodeficiency
virus by enzyme-linked immunosorbent assay was negative. The
isolates were tested for antimicrobial resistance in the Laboratorio
Central de Microbiologia in Tegucigalpa, where an antibiogram
was performed. The antibiogram determined that these isolates
were resistant to amikacin, gentamicin, chloramphenicol, sulfamethoxazole-trimethoprim,
ceftriaxone, and cefoxitin and were sensitive to ciprofloxacin.
Unfortunately, these results were not available before the patient
was discharged for the second time. After the second empirical
treatment, the patient showed an improvement in the clinical
condition and was discharged. However, microbiological eradication
of the
Salmonella infection was not confirmed before discharge,
and attempts to locate the patient after his second stay in
the hospital have failed.
Microbiology and genetic characterization.
The clinical isolate was obtained by the Veterinary Laboratories Agency in the United Kingdom as part of a project focusing on the genetic characterization of ß-lactam resistance. An international collaborative effort with groups in the Universidad de La Rioja (La Rioja, Spain) and Creighton University (Omaha, Nebr.) was adopted to complete this study. The serotype of the isolate (UCM267) was identified as Infantis by following standard methods. It was screened for susceptibility to a panel of 12 ß-lactams plus 12 other antibiotics by using a disk diffusion method (10) and was found to be resistant to ampicillin, amoxicillin plus clavulanic acid, ceftiofur, cefuroxime, ceftazidime, cefotaxime, ceftriaxone, cefoperazone, cefoxitin, cefpodoxime, aztreonam, amikacin, chloramphenicol, colistin sulfate, gentamicin, sulfamethoxazole-trimethoprim, and a triple-sulfonamide solution and sensitive to imipenem, nalidixic acid, neomycin, tetracycline, furazolidone, and streptomycin. MICs of cefoxitin were 128 mg/liter and determined as previously described (6). The resistance phenotype suggested the presence of an extended-spectrum ß-lactamase (ESBL) enzyme and/or the presence of an AmpC ß-lactamase.
The presence of ß-lactamases was assessed by isoelectric focusing (6). Four bands with approximate pI values of 5.2, 8.2, 8.6, and 9 were detected, indicating the production of four enzymes.
The isolate was analyzed by an AmpC multiplex PCR (6) and produced a product consistent with the CIT group (comprises LAT-1 to LAT-4, CMY-2 to CMY-7, and BIL-1). Subsequently, the full-length blaCMY PCR amplicon was sequenced as described before (6) and identified as blaCMY-2. Identification of TEM-, SHV-, and CTX-M-type ß-lactamases was carried out by amplification and sequencing of the respective genes by using methods previously described (1, 11). The amplicons were sequenced on both strands in an Applied Biosystems ABI 310 sequencer, and analysis revealed that the isolate carried a blaTEM-1B variant gene with a silent mutation at base 739 (C to T), a blaSHV-5 gene, and a blaCTX-M-15 gene. In addition, the isolate was positive for class 1 integrons by PCR with primers L2 and L3 located at the conserved region (5). Furthermore, a single amplicon of approximately 1,300 bp was generated by using primers L2 and R1 (7), revealing that the integron contained a single gene cassette encoding the blaSHV-5 determinant.
Preparation of DNA for pulsed-field gel electrophoresis (PFGE) was as described by the U.S. Centers for Disease Control and Prevention (2). Figure 1 shows the XbaI-PFGE fingerprint for the isolate. Plasmid extraction was performed as described previously (6); two plasmids with approximate sizes of 86 and 59.6 MDa were identified.
Assessment of the transferability of resistance.
Conjugations were performed with the
Salmonella serotype Infantis
isolate and a rifampin-resistant recipient
Escherichia coli K-12 20R764, by use of in-broth and filter-mating methods (
6).
Conjugation mixtures were plated on CHROMagar ECC (M-Tech Diagnostics)
containing rifampin (100 mg/liter) and cefotaxime (1 mg/liter)
or CHROMagar ECC containing rifampin (100 mg/liter) and cefoxitin
(32 mg/liter) and then incubated for 24 and 48 h at 37°C.
Transconjugants were obtained only on the cefotaxime plates.
Attempts to transfer resistance to cefoxitin from the
Salmonella serotype Infantis isolate by conjugation consistently failed.
Transformation experiments were conducted as follows: plasmid
DNA was prepared with a QIAGEN high-speed MIDI kit. Electrocompetent
E. coli cells (ElectroMAX DH10B; Invitrogen) were transformed
by electroporation with a Bio-Rad GenePulser II electroporator,
under standard conditions (2 kW, 200

, and 25 µF). Transformants
were selected on nutrient agar containing 32 mg of cefoxitin/liter
after 16 h of incubation at 37°C. Plasmid analysis demonstrated
the acquisition of plasmids of 59.6 and 86 MDa by the transconjugants
and the transformants, respectively. Antimicrobial susceptibility
testing of transconjugants and transformants showed that both
plasmids in isolation were able to confer resistance to the
same ß-lactams. However, the 86-MDa plasmid also conferred
resistance to cefoxitin and aztreonam.
PCR analysis of the transformants carrying the 86-MDa plasmid indicated that the genetic determinants for blaCMY-2 and the class 1 integron with the blaSHV-5 cassette were colocalized on the same plasmid. Also, PCR analysis of the transconjugants carrying the 59.6-MDa plasmid indicated that the genetic determinants for blaTEM-1b and blaCTX-M-15 were colocalized on the same plasmid. Figure 2 illustrates the transfer (by transformation or conjugation) of plasmids of approximately 86 and 59.6 MDa from the Salmonella serotype Infantis isolate to E. coli recipients.
Conclusion.
Salmonella serotype Infantis has previously been reported to
occur in children's infections in hospitals. The first outbreak
due to multiresistant
Salmonella serotype Infantis (including
resistance to several ESBL) affecting hospitalized children
was reported in 1996 in Brazil (
9). These isolates had a single
conjugative plasmid and were sensitive to cefoxitin. There is
a second report, from Brazil in 1999, of a nosocomial outbreak
in a neonatal unit caused by ESBL-producing
Salmonella serotype
Infantis (
12).
Salmonella serotype Infantis has been the second-most-common
serotype in Argentina in recent years, being isolated mostly
from hospitalized pediatric patients (
8). Data presented in
our study document the first description of a
Salmonella isolate
from Central America producing four ß-lactamases.
This strain originated from a pediatric patient that received
two empirical treatments with cephalosporins. It is impossible
to know if the patient was infected with a resistant strain
carrying those genes or if the emergence of resistance was due
to clinical treatment or in vivo transfer of the genetic determinants
from resident flora to the
Salmonella serotype Infantis isolates.
All the genetic determinants responsible for the ß-lactam
resistance were located on potentially transferable plasmids.
Treatment failure of a patient infected with a
Salmonella serotype
Anatum isolate resistant to ceftriaxone has been observed due
to the in vivo acquisition of a plasmid containing the
blaCTX-M-3 gene (
15).
AmpC enzymes confer resistance to a wide spectrum of ß-lactams. In Salmonella serotypes, the majority of AmpC-like enzymes have been reported to be CMY-2. The first report (Salmonella serotype Senftenberg) came from Algeria in 1997 (3), and since then, CMY-2 has been found in the following S. enterica serotypes: Heidelberg, Newport, Typhimurium, Bredeney, Mikawasima, and Montevideo. Also, S. enterica serotype Wien has been found to carry blaCMY-4. This case report represents the first incident of a blaCMY-2 gene in serotype Infantis. The fact that plasmid-mediated AmpC enzymes have been reported by many countries suggests that a global problem has developed.
CTX-M ß-lactamases efficiently hydrolyze many newer broad-spectrum oximino-ß-lactams. CTX-M-producing enterobacteria are endemic in Latin America and in some areas of northeastern Europe. CTX-M enzymes have increasingly been found in Salmonella organisms over recent years. Reports exist for Salmonella serotype Wien with CTX-M-3; Salmonella serotype Virchow with CTX-M-9; Salmonella serotype Infantis with CTX-M-2; Salmonella serotype Typhimurium with CTX-M-4, -5, and -6; Salmonella serotype Anatum with CTX-M-3; Salmonella serotype Oranienburg with CTX-M-3; and Salmonella serotype Enteritidis with CTX-M-3. To the best of our knowledge, we are presenting the first report of CTX-M-15 within the genus Salmonella. Unlike the majority of CTX-M enzymes, CTX-M-15 confers resistance to ceftazidime (13). This enzyme has recently been found in Enterobacteriaceae in India, Poland, Russia, and Turkey, but it had never before been detected on the American continent.
The ESBL SHV-5 was first described to occur in Salmonella serotype Senftenberg in India (14) and has recently been described to occur in Salmonella serotype Typhimurium in Romania. However, it has never been reported to occur in Salmonella serotypes on the American continent.
To date, a total of seven blaTEM-1 molecular variants have been reported due to the pattern of silent mutations in the blaTEM-1 structural gene and in its promoter (from blaTEM-1A to blaTEM-1G) (4). The molecular variant blaTEM-1B has frequently been found in the family Enterobacteriaceae, including in the genus Salmonella (1). The new molecular variant found in our study, with a silent mutation with respect to blaTEM-1b at nucleotide position 739, could be named blaTEM-1H.
In conclusion, this report provides a good example of the emergence of ß-lactamase genes among bacterial species and especially Salmonella serotypes. In addition, this emergence of ß-lactam resistance is not limited to any one country or continent; it is worldwide. This situation is of particular concern to public health, as these mechanisms of resistance now threaten the value of cephalosporin treatment against pathogenic enterobacteria.

ACKNOWLEDGMENTS
We thank E. John Threfall (Health Protection Agency UK) for
careful reading of the manuscript and helpful comments.

FOOTNOTES
* Corresponding author. Present address: Veterinary Laboratories AgencyWeybridge, Department of Food and Environmental Safety, Woodham Ln., Addlestone, KT15 3NB Surrey, England, United Kingdom. Phone: 44 1932 357587. Fax: 44 1932 357595. E-mail:
e.liebana{at}vla.defra.gsi.gov.uk.


REFERENCES
1 - Briñas, L., M. Zarazaga, Y. Sáenz, F. Ruiz-Larrea, and C. Torres. 2002. ß-Lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrob. Agents Chemother. 46:3156-3163.[Abstract/Free Full Text]
2 - Centers for Disease Control and Prevention. 2002. Standardized molecular subtyping of foodborne bacterial pathogens by pulsed-field gel electrophoresis. Centers for Diseases Control and Prevention, Atlanta, Ga.
3 - Koeck, J. L., G. Arlet, A. Philippon, S. Basmaciogullari, H. V. Thien, Y. Buisson, and J. D. Cavallo. 1997. A plasmid-mediated CMY-2 beta-lactamase from an Algerian clinical isolate of Salmonella Senftenberg. FEMS Microbiol. Lett. 152:255-260.[Medline]
4 - Leflon-Guibout, V., B. Heym, and M.-H. Nicolas-Chanoine. 2000. Updated sequence information and proposed nomenclature for blaTEM genes and their promoters. Antimicrob. Agents Chemother. 44:3232-3234.[Abstract/Free Full Text]
5 - Liebana, E., C. Clouting, C. A. Cassar, L. P. Randall, R. A. Walker, E. J. Threlfall, F. A. Clifton-Hadley, A. M. Ridley, and R. H. Davies. 2002. Comparison of gyrA mutations, cyclohexane resistance, and the presence of class I integrons in Salmonella enterica from farm animals in England and Wales. J. Clin. Microbiol. 40:1481-1486.[Abstract/Free Full Text]
6 - Liebana, E., M. Gibbs, C. Clouting, L. Barker, F. A. Clifton-Hadley, E. Pleydell, B. Abdalhamid, N. D. Hanson, L. Martin, C. Poppe, and R. H. Davies. 2004. Characterization of beta-lactamases responsible for resistance to extended-spectrum cephalosporins in Escherichia coli and Salmonella enterica strains from food-producing animals in the United Kingdom. Microb. Drug Resist. 10:1-9.[CrossRef][Medline]
7 - Maguire, A. J., D. F. J. Brown, J. J. Gray, and U. Desselberger. 2001. Rapid screening technique for class 1 integrons in Enterobacteriaceae and nonfermenting gram-negative bacteria and its use in molecular epidemiology. Antimicrob. Agents Chemother. 45:1022-1029.[Abstract/Free Full Text]
8 - Merino, L. A., M. C. Ronconi, M. M. Navia, J. Ruiz, J. M. Sierra, N. B. Cech, N. S. Lodeiro, and J. Vila. 2003. Analysis of the clonal relationship among clinical isolates of Salmonella enterica serovar Infantis by different typing methods. Rev. Inst. Med. Trop. Sao Paulo 45:119-123.[Medline]
9 - Moraes, B. A., C. A. Cravo, M. M. Loureiro, C. A. Solari, and M. D. Asensi. 2000. Epidemiological analysis of bacterial strains involved in hospital infection in a university hospital from Brazil. Rev. Inst. Med. Trop. Sao Paulo 42:201-207.[Medline]
10 - NCCLS. 1999. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Approved standard. NCCLS document M31-A. NCCLS, Wayne, Pa.
11 - Pagani, L., E. Dell'Amico, R. Migliavacca, M. M. D'Andrea, E. Giacobone, G. Amicosante, E. Romero, and G. M. Rossolini. 2003. Multiple CTX-M-type extended-spectrum ß-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J. Clin. Microbiol. 41:4264-4269.[Abstract/Free Full Text]
12 - Pessoa-Silva, C. L., C. M. Toscano, B. M. Moreira, A. L. Santos, A. C. Frota, C. A. Solari, E. L. Amorim, G. Carvalho Mda, L. M. Teixeira, and W. R. Jarvis. 2002. Infection due to extended-spectrum beta-lactamase-producing Salmonella enterica subsp. enterica serotype Infantis in a neonatal unit. J. Pediatr. 141:381-387.[CrossRef][Medline]
13 - Poirel, L., M. Gniadkowski, and P. Nordmann. 2002. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J. Antimicrob. Chemother. 50:1031-1034.[Abstract/Free Full Text]
14 - Revathi, G., K. P. Shannon, P. D. Stapleton, B. K. Jain, and G. L. French. 1998. An outbreak of extended-spectrum, beta-lactamase-producing Salmonella Senftenberg in a burns ward. J. Hosp. Infect. 40:295-302.[CrossRef][Medline]
15 - Su, L.-H., C.-H. Chiu, C. Chu, M.-H. Wang, J.-H. Chia, and T.-L. Wu. 2003. In vivo acquisition of ceftriaxone resistance in Salmonella enterica serotype Anatum. Antimicrob. Agents Chemother. 47:563-567.[Abstract/Free Full Text]
Journal of Clinical Microbiology, October 2004, p. 4885-4888, Vol. 42, No. 10
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.10.4885-4888.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Liebana, E., Batchelor, M., Hopkins, K. L., Clifton-Hadley, F. A., Teale, C. J., Foster, A., Barker, L., Threlfall, E. J., Davies, R. H.
(2006). Longitudinal Farm Study of Extended-Spectrum {beta}-Lactamase-Mediated Resistance.. J. Clin. Microbiol.
44: 1630-1634
[Abstract]
[Full Text]
-
Rankin, S. C., Whichard, J. M., Joyce, K., Stephens, L., O'Shea, K., Aceto, H., Munro, D. S., Benson, C. E.
(2005). Detection of a blaSHV Extended-Spectrum {beta}-Lactamase in Salmonella enterica Serovar Newport MDR-AmpC. J. Clin. Microbiol.
43: 5792-5793
[Abstract]
[Full Text]
-
Yong, D., Lim, Y. S., Yum, J. H., Lee, H., Lee, K., Kim, E.-C., Lee, B.-K., Chong, Y.
(2005). Nosocomial Outbreak of Pediatric Gastroenteritis Caused by CTX-M-14-Type Extended-Spectrum {beta}-Lactamase-Producing Strains of Salmonella enterica Serovar London. J. Clin. Microbiol.
43: 3519-3521
[Abstract]
[Full Text]
-
Batchelor, M., Hopkins, K. L., Threlfall, E. J., Clifton-Hadley, F. A., Stallwood, A. D., Davies, R. H., Liebana, E.
(2005). Characterization of AmpC-Mediated Resistance in Clinical Salmonella Isolates Recovered from Humans during the Period 1992 to 2003 in England and Wales. J. Clin. Microbiol.
43: 2261-2265
[Abstract]
[Full Text]